secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001370053-24-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports Q4 2023 net loss of $42.2M, cash $417.9M; pipeline on track
------------------------------------------------------------------------------

- Q4 net loss $42.2M ($1.59 per share); full-year net loss $163.6M ($6.08 per share).
- Cash & investments $417.9M at Dec 31, 2023 (down from $584.2M year-end 2022); runway through 2026.
- R&D spend $33.5M in Q4, up 43% YoY, driven by rosnilimab, ANB032, and ANB033 manufacturing.
- ANB032 Phase 2b atopic dermatitis top-line data expected by year-end 2024; rosnilimab RA data mid-2025, UC data H1 2026.
- IND filings for ANB033 (anti-CD122) in Q2 2024 and ANB101 (BDCA2) in H2 2024; ANB101 licensed for $7M upfront.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/0001370053-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005324000010/anab-20240311.htm
  HTML page:      https://secwatch.observer/filing/0001370053-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer